Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 62Carcinoma, Hepatocellular 25Neoplasm Metastasis 15Rectal Neoplasms 11Colonic Neoplasms 10Gastrointestinal Stromal Tumors 9Sarcoma 6Ovarian Neoplasms 5Osteosarcoma 5Glioblastoma 5Cholangiocarcinoma 5Stomach Neoplasms 4Melanoma 4Liver Neoplasms 4Sarcoma, Ewing 3Pancreatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Colorectal Carcinoma × regorafenib × Clear all
NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Peking Union Medical College Hospital

Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡